Bi et al.[11] demonstrated that the ability of fluoxetine to inhibit sphingomyelin phosphodiesterase 1 (SMPD1), a key protein required for lipid synthesis, was a potential mechanism for the anti-glioblastoma effects of fluoxetine. The gene discussed is SMPD1; the disease is glioblastoma.